COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #95 of 258
7/21 Late treatment study
Bernaola et al., medRxiv, doi:10.1101/2020.07.17.20155960 (Preprint)
Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Source   PDF   Share   Tweet
HCQ HR 0.83 [0.77-0.89] based on propensity score matched retrospective analysis of 1,645 hospitalized patients. Prednisone HR 0.85 [0.82-0.88], 14 other medications showed either no signicant benefit or a negative effect.

Bernaola et al., 7/21/2020, retrospective, Spain, Europe, preprint, 7 authors.
risk of death, 17.0% lower, RR 0.83, p < 0.001, treatment 236 of 1498 (15.8%), control 28 of 147 (19.0%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 258 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit